COVID-19 and Tuberculosis
As SARS-CoV-2 spread, the HVTN was tapped to apply its clinical, statistical and operational infrastructure to rapidly design, implement and analyze the U.S. Government-supported Phase 3 clinical trials of COVID-19 vaccines.
The COVID-19 Prevention Network (CoVPN), funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), was formed in spring 2020 to create a coordinated, efficient and scientifically rigorous approach to developing the COVID-19 vaccines in order to help end the pandemic.
In partnership with the AIDS Clinical Trials Group (ACTG) and International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HVTN is conducting an integrated clinical trials program for TB that includes immunological, microbiological and diagnostic technologies. This will enhance the TB vaccine field globally by evaluating the safety and immunogenicity of TB vaccines for all age groups. We seek to identify vaccines that (1) prevent TB infection, (2) prevent progression from TB infection to disease, and (3) reduce the risk of unfavorable treatment outcomes, particularly treatment failure and recurrent TB, and post-treatment morbidity and mortality when used adjunctively with TB treatment.